The push to get better, faster vaccine technology in place took a step forward with the news that France's Vivalis and GlaxoSmithKline have won FDA approval to begin clinical trials of a new flu jab using duck stem cell line EB66 technology. Vivalis says the regulatory green light could pave the way to an approval for the first such new vaccine as early as 2015. Story